See our recent news and announcements below. If you have any questions or for media inquiries, please contact email@example.com for assistance or see specified media contact details within each release.
Waltham, MA, May 20, 2021 –
Pyramid Biosciences, Inc., a clinical-stage, biotechnology company developing novel precision therapies, announced that it has commenced a Phase 1 clinical study for its therapeutic candidate PBI-100, a first-in-class topical treatment targeting mild to moderate psoriasis in patients. Psoriasis is an immune-mediated skin disease1, where an overactive immune system causes a rapid increase in keratinocyte production that can lead to raised, flaking skin lesions. People living with psoriasis report symptoms such as itching, burning and stinging. [click to read more]